Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Public Citizen continues to press Meridia withdrawal

Executive Summary

Public Citizen submits second petition calling for FDA to ban Abbott's diet drug Meridia (sibutramine). The first petition, submitted March 19, 2002, cited 19 deaths from cardiovascular disease from February 1998 to September 2001. The 1second petition, submitted Sept. 3, includes 30 additional reports of cardiovascular deaths in Meridia patients. Abbott met with FDA Chief Counsel Dan Troy June 11 to discuss Meridia labeling (2"The Pink Sheet" July 21, 2003, In Brief)...

You may also be interested in...



Sanofi Chews The Fat: Rimonabant Anti-Obesity NDA To Be Filed By 2005

Sanofi-Synthelabo expects to file an NDA for rimonabant in obesity by the first quarter of 2005, Exec VP-Scientific Affairs Gerard Le Fur told analysts during a business review in London Sept. 2

Meridia labeling

Abbott met with FDA Chief Counsel Daniel Troy July 11 to discuss labeling issues for Meridia (sibutramine). Public Citizen's petition requesting withdrawal of the obesity agent has been pending at FDA since March 2002 (1"The Pink Sheet" March 25, 2002, p. 21)...

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel